Analyst price target for SOLV is US$87.18 which is 35% below our fair value estimate Does the January share price for ...

Wondering if Recursion Pharmaceuticals at around US$4.67 a share is priced for its potential or still misunderstood by the ...

Global equity markets are up, but Q4 earnings season has begun, and the time of reckoning is here. Companies will either show ...

We use our proprietary models to rate both quantitatively and qualitatively, and select the top 10 names from an initial list ...

OpenAI CEO Sam Altman has had an unfortunate dose of reality, reckoning with the fact ChatGPT is a uniquely powerful money ...

Why today’s AI systems struggle with consistency, and how emerging world models aim to give machines a steady grasp of space ...

AI is monetizing human behavior at scale. Why platforms like OnlyFans signal a structural shift and where investors should ...

For decades, I led state health and human services agencies and dealt directly with federal bureaucracies that write the ...